Condition: Ovarian Cancer · Ovarian Cancer Recurrent · Sponsor: Compugen Ltd
The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701. The main questions the trial aims to answer are: * Does COM701, when used as a maintenance treatment, stop or slow the progression of ovarian cancer? * Does COM701 delay the time to needing a new anti-cancer treatment? * What side effects do participants have when taking COM701? Participants will: * Visit the clinic once every 3 weeks during which the study treatment will be administered intravenously * Undergo various tests and procedures to monitor general health throughout the trial including physical examinations, vital sign measurements (heart rate, blood pressure, breathing, and body temperature), weight measurements, electrocardiography (ECG), blood and urine tests and pregnancy tests if relevant. * Undergo various tests and procedures to assess disease response throughout the trial including tumor imaging by CT scans or MRI to assess the tumor, its location, and size, and the testing of a sample of tumor tissue (from a prior biopsy or a fresh biopsy if feasible, to evaluate tumor response to treatment and to measure levels of tumor markers,
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Georgia Cancer Center at Augusta University | Augusta, Georgia, United States | Recruiting |
| The University of Chicago Medical Center | Chicago, Illinois, United States | Recruiting |
| Northwestern Memorial Hospital | Warrenville, Illinois, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Corewell Health | Grand Rapids, Michigan, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center- Main Campus | New York, New York, United States | Recruiting |
| University of Rochester Medical Center | Rochester, New York, United States | Recruiting |
| Levine Cancer Institute | Charlotte, North Carolina, United States | Recruiting |
| Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run | Hilliard, Ohio, United States | Recruiting |
| OU Health Stephenson Cancer Center | Oklahoma City, Oklahoma, United States | Recruiting |
| UPMC Magee- Womens Hospital | Pittsburgh, Pennsylvania, United States | Recruiting |
| Avera Cancer Institute | Sioux Falls, South Dakota, United States | Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06888921